PHASE II STUDY OF COMBINATION OF PEMETREXED (ALIMTA®) AND CISPLATIN AS FIRST-LINE TREATMENT OF STAGE IV STOMACH CANCER OR RECURRENT GASTRIC CANCER


Cite item

Full Text

Abstract

The article is dedicated to the results of study which was aimed to evaluation the efficacy and safety of combination of pemetrexed and cisplatin (700 mg/m2 and 75 mg/m2, respectively) as the first-line therapy, and analysis of progression-free survival (PFS), overall survival (OS) and duration of effect in 53 patients with generalized gastric adenocarcinoma (IV stage) or recurrent gastric cancer. Objective response rate was 32.1% and the rate of disease control - 58.5%. The median duration of effect was 3.8 months, median PFS - 3.7 and the median OS - 8.8 months. The most frequent III-IV grade drug-induced hematologic toxicity was neutropenia (54.7%); in other cases hematologic toxicity led to anemia, thrombocytopenia, alopecia and rash. Study has demonstrated moderate effectiveness and satisfactory safety profile of this treatment regimen. Rate of disease control, equal to 58.5%, indicates the effectiveness of combination at this stage of the disease in this patient population

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
  2. Davidov MI, Aksel EM, Vestnik NN. Blokhin Russian Cancer Research Center, RAMS 2009;20:(3 Suppl. 1).
  3. Chissov VI, et al. Russian Cancer Registry, 2009. Swan R, Miner TJ. Current role of surgical therapy in gastric cancer. World J Gastroenterol 2006;12:372-79.
  4. Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14(Suppl. 2):ii31-ii6.
  5. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systemic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
  6. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
  7. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
  8. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-7.
  9. Kim NK, Park YS, Heo DS, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-8.
  10. Shih C, Habeck LL, Mendelsohn LG, et al. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998;38:135-52.
  11. Taylor EC, Kuhnt D, Shih C, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4.
  12. Schultz RM, Patel VF, Worzalla JF, et al. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999;19:437-43.
  13. Chen VJ, Bewley JR, Andis SL, et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 1998;78(Suppl. 3):27-34.
  14. Kim JH, Lee KW, Jung Y, et al. Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer Sci 2005;96:365-71.
  15. Hanauske AR, Chen V, Paoletti P, et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001; 6:363-73.
  16. Bajetta E, Celio L, Buzzoni R, et al. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 2003;14:1543-8.
  17. Celio L, Sternberg CN, Labianca R, et al. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Ann Oncol 2009;20:1062-7.
  18. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409-22.
  19. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
  20. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
  21. Kim YH, Chung HC, Kang WK, et al. Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. Cancer Chemother Pharmacol 2008;62:263-70.
  22. Chen JS, Chao Y, Bang YJ, et al. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anticancer Drugs 2010;21:777-84.
  23. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 5th ed. Fleming ID, Cooper JS, Henson DE, et al, editors. Philadelphia, PA: Lippincott-Raven Publishers, 1997.
  24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
  25. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
  26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
  27. ICH Efficacy Guidelines. E6(R1): Good Clinical Practice: Consolidated Guideline. Finalized 1996. Available at: http://www.ich.org/cache/compo/475-272-1.html.
  28. Ozer H, Armitage JO, Bennett CL, et al; American Society of Clinical Oncology Growth Factors Expert Panel. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558-85.
  29. National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Published 2006. Available at: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
  30. Etienne MC, Formento JL, Chazal M, et al. Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 2004;14:785-92.
  31. Ruzzo A, Graziano F, Kawakami K, et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol 2006;24:1883-91.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies